Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LOQTORZI

(Toripalimab-tpzi)

Small molecule

CCoherus Oncology, Inc.

0

Indications

3

Total Trials

2

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Squamous Cell Carcinoma

NCT07214987

Q1 2031

Phase 1Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07898124

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma of Head and Neck1 trial

Phase 1 Study of TMV Vaccine Alone or TMV Vaccine Plus Toripalimab-tpzi in Loco-Regionally Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting·MMetaclipse Therapeutics Corporation·Phase 1·NCT07898124·30 enrolled

Squamous Cell Carcinoma1 trial

A Phase 2 Study of Toripalimab in Combination With Cisplatin and Docetaxel (PDT) for Induction Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting·MMassachusetts General Hospital·Phase 2·NCT07214987·26 enrolled

Ovarian Cancer Stage IV1 trial

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Withdrawn·GGeorgetown University·Phase 2·NCT05479045

Regulatory

FDA Approval Timeline[3]

Oct 27, 2023

LOQTORZI

BLA BLA761240

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Toripalimab-tpzi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Toripalimab-tpzi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (BLA BLA761240). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Coherus Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CCoherus Oncology, Inc.

Related News